Contrasting Effects Of WIN 55212—2 On Motility Of The Rat Bladder And Uterus

Thread starter #1

Both the uterus and bladder contain cannabinoid (CB) receptors whose functions are poorly understood. Here, in urethane-anesthetized female rats in metestrus, we simultaneously compared the effects of close-arterial injections of the cannabinoid receptor agonist WIN 55,212—2 (WIN2) on uterine contractions (amplitude and rate) and micturition thresholds (MT) assessed by cystometry. Five doses of WIN2 were delivered (0.01, 0.1, 0.5, 1, and 1.5 μmol/kg) in three groups: (1) controls; (2) after bladder inflammation with intravesicular turpentine; and (3) after bilateral hypogastric neurectomy (HYPX). In some rats, drugs were delivered via the tail vein. Regarding bladder, WIN2 dose-dependently reduced MTs in all groups. Both bladder inflammation and HYPX significantly increased this effect. Regarding uterus, WIN2 dose-dependently increased uterine contraction amplitude. Bladder inflammation or HYPX significantly decreased this effect. Coinjection of the CB1 antagonist SR141716A (SR) (1.5 μmol/kg) and WIN2 (0.5 μmol/kg) abolished or reduced the effects of WIN2 in both organs. SR alone had significant effects only after HYPX, reducing both MT and uterine contraction amplitude. The vehicle (0.4% DMSO) and inactive enantiomerS(−)-WIN 55,212—3 were both ineffective. Close-arterial injections of WIN2 (0.5 μmol/kg) produced significantly larger effects in both organs than tail vein injections. These results indicate that, whereas WIN2 reduces bladder motility, it mainly increases uterine motility, likely via CB1 receptors located in the two organs. The opposing effects of bladder inflammation and HYPX on the potency of WIN in the two organs suggest a neurally mediated viscero-visceral interaction in which bladder inflammation influences uterine CB1 sensitivity, possibly by inhibiting adrenergic input to the uterus.


Numerous anecdotal reports indicate that cannabinoids (CBs) affect uterine and bladder motility. Thus, cannabis has been used for more than a century to treat dysmenorrhea and menorrhagia (O'Shaughnassy, 1842; Abel, 1980). Furthermore, multiple sclerosis patients report that cannabis alleviates their nocturia and bladder hyperactivity and pain (Consroe et al., 1997); so does Δ9-tetrahydro-cannabinol (Δ9-THC) (Martyn et al., 1995). Recently, the CB1 receptor was identified in both rodent bladder (Pertwee and Fernando, 1996; Martin et al., 2000) and uterus (Das et al., 1995). CB1 receptors were also identified in terminals of peripheral sensory afferent and sympathetic fibers (Hohman and Herkenham, 1999; Niederhoffer and Szabo, 1999; Malinowska et al., 2001;Niederhoffer et al., 2001).

Together, these reports suggest involvement of local cannabinoid receptors, particularly CB1 receptors, in regulating uterine and bladder function. Indeed, the endogenous cannabinoid ligand anandamide and endometrial CB1 receptors participate in regulating receptivity of the mouse uterus for embryo implantation (Schmid et al., 1997; Paria and Dey, 2000). For the bladder, different cannabinoid receptors may become engaged depending on its state; i.e., healthy versus inflamed. Thus, bladder mast cells, which express the CB2 receptor (Facci et al., 1995), increase dramatically during bladder inflammation (Christmas and Rode, 1991; Sant and Theoharides, 1994). Furthermore, Jagger et al. (1998a,b) compared effects of systemic delivery of anandamide and palmitoylethanolamide (PEA) before and after bladder inflammation on inflammation-induced bladder hyperreflexia. Because both agents reduced hyperreflexia after inflammation, but only anandamide prevented hyperreflexia before inflammation, they concluded that CB2 receptors become involved in regulating bladder motility only after inflammation (Jagger et al., 1998a). These results, however, do not necessarily imply direct activation of CB2 receptors, because PEA does not bind directly to them (Showalter et al., 1996; Jonsson et al., 2001).

Here we developed a protocol to characterize the influence of cannabinoid agents simultaneously on bladder and uterine motility. We then used this protocol to examine effects of close-arterial injections of the mixed CB1/CB2 receptor agonist R(+)-WIN 55,212—2 (WIN2) on the frequency and amplitude of uterine contractions and on cystometrically measured micturition thresholds (MTs) before and after bladder inflammation (i.e., on the volume of saline infused into the bladder that induced a bladder contraction). To determine the contribution of CB1 receptors, we examined effects when WIN2 was delivered together with the CB1-specific antagonist SR141716A (SR). To provide evidence about the site of action of the ligand, we compared responses when the same dose of WIN2 was injected close-arterially or via the tail vein.

Hypogastric nerve activity can inhibit micturition (de Groat and Theobald, 1976) and is involved in controlling uterine activity and nociception (Sato et al., 1989, 1996; Temple et al., 1999; Dmitrieva et al., 2001). Because WIN2 modulates sympathetic activity in rodents (Malinowska et al., 1997; Niederhoffer and Szabo, 1999) and Δ9-THC inhibits noradrenaline release in rat isolated atria and vas deferens (Ishac et al., 1996), it is possible that cannabinoids influence bladder and uterine motility via the hypogastric nerve. We tested this hypothesis by studying effects of WIN2 after bilateral


Animal preparation
Adult female Sprague Dawley rats (220—270 gm) were used. They were housed individually in transparent plastic cages with chip bedding and maintained on a 12 hr light/dark cycle. Before the experiment, their estrous stages were monitored daily via vaginal smears obtained 2 hr after lights on for at least 3 weeks before the experiment. Only rats with at least three regular 4 d estrous cycles were used. They were in metestrus on the day of the experiment.

Rats were anesthetized with urethane (1.2 gm/kg, supplemented as needed). Body temperature was maintained at ∼37°C throughout the experiment by a heating pad and warming lamp. To prepare for close-arterial injections, an incision was made in the skin of the inner left hindleg. The femoral artery was freed from the surrounding tissue and separated from the vein. A thin polyethylene catheter (outer diameter of 0.61 mm) was inserted deeply into the femoral artery (2.0—2.5 mm) so that its tip rested near arterial branches to the bladder and left uterine horn. It was then secured in place (Fig.1). In some rats, the tail vein was catheterized instead of the femoral artery.

To prepare for cystometrograms (CMGs), the bladder was catheterized transurethrally with polyethylene tubing (outer diameter of 0.97 mm), with the tip of the catheter placed ∼2 mm within the lumen of the bladder so that the tip did not contact the bladder walls (Fig. 1). A suture was tied around the surrounding skin to prevent leakage.

To prepare for measuring the amplitude and rate of uterine contractions, a ventral midline incision was made to expose the bladder and left uterine horn. In all rats, a small incision was made near the midrostral end of the left uterine horn. A water-filled catheter with a small latex balloon on its end (diameter of ∼2 mm) was inserted into the lumen so that the balloon, secured by a stitch, rested ∼1 cm above the uterine body. The uterine catheter was connected to another small-volume pressure transducer and amplifier (Fig. 1). The abdomen was covered with a saline-dampened pad. Both the bladder and uterine catheters were then connected to small-volume pressure transducers, whose signals were amplified and relayed to strip chart and videotape recorders for offline analyses.

For bladder motility, MTs were assessed via CMGs, which measured pressure within the bladder while it was slowly filled (0.05 ml/min) with saline via the transurethral catheter to a maximum volume of 1 ml (to avoid overinflation). MT was defined as either the intraluminal volume that produced the first micturition contraction, or, if no contraction occurred (rarely), 1 ml. Figure 1 provides an example CMG record.

Uterine contractions
The amplitude and frequency of spontaneous uterine contractions were recorded as they passed over the uterine balloon and were measured manually from the strip chart records (Fig. 1). Mean amplitude of uterine contractions was calculated from three to five contractions that were measured between the times that CMGs were being run. Mean rate of uterine contractions was calculated in 5 min intervals during a 25 min period before and a 30 min period after administration of each drug.

Bladder inflammation
After the baseline MT was established, 0.5—0.8 ml of 50% turpentine oil (in olive oil) was instilled into the bladder. At approximately hourly intervals afterward, the bladder was emptied by gentle pressure and suction, and additional CMGs were performed.

Bilateral hypogastric neurectomy
In some rats, just before the uterus was catheterized, the left and right hypogastric nerves were identified as they exited caudally from the inferior mesenteric ganglion (IMG). A 1 cm length of both nerves was freed from surrounding connective tissue. A snare of 4.0 silk suture was loosely tied around each nerve. At the appropriate point in the experiment, each snare could be pulled through the hypogastric nerves to cut them (HYPX). This technique had been used successfully previously to cut the vagus nerve (Hubscher and Berkley, 1995). Baseline MT was also established before HYPX.

Experimental design
Study 1: dose—response to WIN2. A dose—response function for close-arterial injections of WIN2 was obtained using five doses of WIN2 (0.01, 0.1, 0.5, 1, and 1.5 μmol/kg) and compared with the effect of a high dose of the inactive enantiomerS(−)-WIN 55,212—3 (WIN3) (1 μmol/kg) and the vehicle (0.4% DMSO). The agents were tested in three different groups of rats: (1) control group, rats without either bladder inflammation or HYPX, (2) rats with bladder inflammation, and (3) rats with HYPX. All rats received a close-arterial injection of the vehicle and/or WIN3 before one or two doses of WIN2 were delivered. The drugs were tested 2—5 hr after the onset of inflammation because previous reports have demonstrated that the maximum bladder hyperreflexia develops by 2 hr and is maintained for an additional 3 hr (McMahon and Abel, 1987;Dmitrieva et al., 1997). In the HYPX group, all treatments were performed 2—4 hr after neurectomy because previous studies have shown that MTs are decreased beginning 1.5 hr after HYPX (Dmitrieva and Berkley, 2001).

Study 2: influence of CB1 antagonist. Three groups of rats (control, bladder inflammation, and HYPX) received close-arterial codelivery of WIN2 and SR (0.5 and 1.5 μmol/kg, respectively). In the other two groups (normal and HYPX), only SR (1.5 μmol/kg) was injected.

Study 3: close-arterial versus tail vein. One group of intact controls (i.e., without either bladder inflammation or HPYX) received one dose of WIN2 (0.5 μmol/kg) delivered via the tail vein.

The general protocol for all three studies was as follows. After surgical preparations, two or three baseline CMGs were performed at ∼30 min intervals before any treatment. Next, either nothing was done (control group) or the bladder was inflamed or HYPX was performed by pulling the snares through the nerves. CMGs were then repeated in control rats, or 2—3 hr after bladder inflammation, or 2 hr after HYPX. The vehicle was then injected. Ten minutes after vehicle injection, another CMG was obtained. After "recovery" from the vehicle (< 20 min, effects were negligible), another agent (WIN3, or one dose of WIN2 or WIN2 plus SR or SR alone) was delivered. Approximately 10 min later, another CMG was obtained. After recovery from the first dose of WIN2, CMGs were repeated at 1 hr intervals until recovery occurred (1.5—2 hr; see Results). Then another dose of WIN2 was delivered, and the process was sometimes repeated once more. An example of such a protocol for two doses of WIN2 is shown in Figure2. For any one subject, at most, three doses of WIN2 in addition to the vehicle control were tested in haphazard order.

Data analysis and statistics
The mean change in MTs and uterine contraction amplitude before and after drug administrations and the time at which full recovery from the previous dose occurred were tested as appropriate by Student'st test or one- or two-way repeated-measures ANOVAs, followed by Dunnett's post hoc analysis. Changes in the rate of uterine contractions were analyzed using the Friedman test, followed by Wilcoxon post hoc tests. Significance levels were set atp < 0.05.

The active cannabinoid receptor agonist WIN2 and the inactive enantiomer WIN3 were purchased from Sigma (St. Louis, MO). The specific CB1 receptor antagonist SR was a gracious gift from the National Institute of Drug Abuse (Bethesda, MD). Drugs were diluted with saline from a stock solution of 50 mM dissolved in 100% DMSO. All drugs were delivered by slowly injecting them in a volume of 0.1—0.15 ml and then flushing the drug thorough with 0.1 ml of heparinized saline.


Effects of bladder inflammation and HYPX on bladder and uterine motility
As expected from numerous previous studies (McMahon and Abel, 1987; Dmitrieva et al., 1997), bladder inflammation significantly decreased MTs (Fig. 3, compare the first CMG record with a baseline CMG that is shown in Fig. 1). The mean decrease here was 0.38 ± 0.05 ml (mean ± SE;p < 0.001). As also expected, HYPX significantly decreased MTs but to a lesser extent: 0.2 ± 0.06 ml (mean ± SE; p < 0.05). Unexpectedly, bladder inflammation also significantly affected uterine motility by decreasing uterine contraction rate. HYPX, on the other hand, significantly affected uterine motility mainly by increasing contraction amplitude. These latter two findings have been reported in full previously (Dmitrieva et al., 2001).

Effects of WIN2 on bladder motility
As shown in Figure 3, WIN2 significantly increased MTs in a dose—response manner in all groups. The effects after bladder inflammation and HYPX did not differ significantly from each other, but both were significantly greater than in the intact, uninflamed condition (p < 0.05). Note that neither DMSO alone nor WIN3 (1 μmol/kg) produced effects on MT in any condition. Examples of some of the effects of WIN2 on MTs are shown in Figure2.

In most rats, WIN2 had been injected more than once in different doses. When this procedure was followed, WIN2 was administered only after the MT from the previous dose had returned to the preinjection value (Fig.2). This recovery period in all cases was ∼1.5—2 hr (confirmed by ANOVA; p > 1.0).

Effects of WIN2 on uterine motility
To determine whether repetitive CMGs might influence the response of the uterus to WIN2, the bladder of three to four rats in each group was catheterized, but CMGs were not done. The responses of the uterus to WIN2 in these two groups did not differ (results not shown); therefore, the data from both groups was combined. The combined results are presented in Figure 4.

In contrast to the reduction of bladder motility by WIN2 (i.e., increased MTs), WIN2 significantly increased uterine motility. Figure 4shows that WIN2 increased the amplitude of uterine contractions in a dose-dependent manner (p < 0.001) in control rats, as well as in rats with bladder inflammation (p < 0.005) but not in rats with HYPX (p > 0.3). The latency of this effect was <1 min. However, again in contrast with the bladder, the effect of WIN2 on uterine contraction amplitude was reduced after bladder inflammation and nearly abolished after HYPX. Thus, the effect of 1.5 μmol/kg WIN2 in the rats with an inflamed bladder was significantly smaller than in control rats (p < 0.05). In HYPX rats, the response to 1 and 1.5 μmol/kg WIN2 was significantly lower compared with that observed in control rats (p < 0.05 and 0.01 for 1 and 1.5 μmol/kg, respectively).

WIN2 influenced the rate of uterine contractions to a lesser extent than it did the amplitude of uterine contractions (results not shown). The two highest doses decreased the rate only briefly (∼20 min) in control rats, as well as a middle dose (0.5 μmol/kg) in HYPX rats (p < 0.05). There were no significant effects in rats with bladder inflammation.

DMSO and WIN3 failed to produce significant effects on uterine motility in any condition.

Effects of the CB1 antagonist SR141716A
As shown in Figure5 A, injections of SR plus WIN2 prevented reductions by WIN of MTs in all groups (p < 0.005, significant difference between the effect of SR plus WIN2 and WIN2 alone). As shown in Figure5 B, SR plus WIN2 also prevented increases by WIN2 of uterine contraction amplitude in control rats and those with bladder inflammation (p < 0.05) but not in rats with HYPX.

Control rats and those with HYPX were also treated with 1.5 μmol/kg SR alone. Both MTs and uterine contraction amplitudes were significantly reduced with HYPX (p < 0.05) (Fig. 5 A,B) but were unchanged in control rats.

Close-arterial versus tail vein injections
As shown in Figure 6, the effects of WIN2 on both the bladder and uterus were significantly greater when injected via the close-arterial route than via the tail vein (p < 0.05).


Using a procedure that permits simultaneous observation of bladder and uterine motility, we found that, whereas WIN2 dose-dependently decreased bladder motility, it dose-dependently increased uterine motility in healthy control rats. Whereas both bladder inflammation and HYPX increased the effects of WIN2 on the bladder, the two manipulations decreased the effects of WIN2 on the uterus. These results indicate that cannabinoids exert opposing actions on the bladder and uterus.

When the CB1 receptor antagonist SR was coinjected with WIN2, the effects of WIN2 in both organs were reduced or abolished, suggesting that at least some of those effects occurred by way of CB1 receptors in both organs. WIN2 was more effective when injected close to the organs than when injected via a more circuitous systemic route through the tail vein, supporting the conclusion that some of the effects occurred locally within the organs.

Effects of cannabinoids on bladder motility
The results here on the bladder support previous studies demonstrating the existence of CB1 receptors in the bladder, which, when activated, reduce bladder motility (Pertwee and Fernando, 1996;Martin et al., 2000). The fact that, in the present study, bladder inflammation increased the potency of WIN2 suggests an upregulation of CB1 receptors in the bladder in this condition. This suggestion is supported by recent findings that CB1 receptors are upregulated in the mouse intestine after intestinal inflammation (Izzo et al., 2001).

Previous studies have suggested that CB2 receptors become involved in bladder hyperreflexia after bladder inflammation (Jagger et al., 1998b) and that both CB1 and CB2 receptors are involved in the referred hyperalgesia that is produced by bladder inflammation (Farquhar-Smith and Rice, 2001). What was somewhat surprising here, therefore, is that the effects of WIN2, which is a mixed CB1/CB2 agonist (Pertwee, 1999), were completely, rather than only partially, reversed by SR. Although this result suggests that, even in the inflamed bladder, all of the effects of WIN2 may have occurred by way of CB1 receptors, definitive support for this suggestion requires demonstrating that close-arterial injections of a CB2 antagonist do not alter the effects of WIN2. Furthermore, it is possible that WIN2 acts on CB2 receptors at higher doses than the middle dose tested here, but that seems unlikely, because, although WIN2 is a CB1 and CB2 receptor antagonist, it actually exhibits a "marginal selectivity for CB2 receptors" (Pertwee, 1999).

The fact that the same dose of WIN2 was more effective in reducing MT when delivered by close-arterial injection than by tail vein injection suggests that the effects were occurring locally within the bladder, possibly on peripheral afferent receptors or sympathetic terminal fibers (Ishac et al., 1996; Richardson et al., 1998; Malinowska et al., 2001). It is likely that the effects were not entirely local, however, because CB1 receptors have been identified or shown to act in rat brainstem sites in the vicinity of regions that control bladder function, such as periaqueductal gray, pons, hypothalamus, and basal ganglia (Matsuda et al., 1993; Fowler, 1998; Pettit et al., 1998;Athwal et al., 2001; Palazzo et al., 2001), as well as in lumbar spinal cord (Hohmann et al., 1999; Drew et al., 2000).

The mechanism by which HYPX increased the potency of WIN2 on the bladder likely differs from that produced by bladder inflammation. Indeed, this increased potency was surprising, given reports that sympathetic terminals might contain CB1 receptors (Malinowska et al., 2001). The receptors in that study, however, supplied the heart, and the same situation may not apply to the sympathetic supply of the bladder. Studies on heteroreceptor interactions in guinea pig hippocampus slices suggest that cannabinoid receptors may influence tonic inhibition from α2-adrenoreceptors (Schlicker et al., 1997;Schlicker and Göthert, 1998). If this type of interaction is the case within the bladder, increased sensitivity to WIN2 in denervated bladder may be attributable to a disinhibition of local CB1 receptors, possibly located on peripheral pelvic nerve afferents like they are in other lumbar spinal afferents (Hohmann and Herkenham, 1999;Ahluwalia et al., 2000).

Effects of cannabinoids on uterine motility
In intact, uninflamed control rats, WIN2 increased the amplitude of uterine contractions with only minor effects on the rate of contractions at the highest doses. The effects were eliminated by coadministration of SR. These results support previous studies demonstrating the expression of CB1 receptors in the rodent uterus (Das et al., 1995).

However, whereas coadministration of SR and WIN2 eliminated the effect of WIN2 on the uterus in control rats and rats with an inflamed bladder, it failed to do so in HYPX rats. Furthermore, treatment with SR alone significantly reduced uterine contraction amplitude. These findings suggest that functional CB1 receptors may still be present in the neurectomized uterus, supporting a postsynaptic action of WIN2 in the uterus. One such postsynaptic mechanism could be an interaction between CB1 and postsynaptic adrenergic receptor signal-transduction mechanisms in the uterus. The α-adrenergic receptor is a likely candidate for this role because its activation has been found to increase uterine motility (Ibuki et al., 1997). Cocaine also has been found to exert a stimulatory effect in the uterus, acutely increasing the contraction duration of human myometrial strips (Monga et al., 1993). The mechanism of cocaine action in the human uterus has been suggested to be an inhibition of cAMP production induced by activating adrenoreceptors (Wang et al., 1996). The cAMP is a converging point for signal-transduction pathways activated by different modulators of uterine contractility (Okamura et al., 2000). Reports showing that cannabinoid agonists such as Δ9-THC and anandamide inhibited the forskolin-stimulated cAMP formation in endometrium through activation of the CB1 receptor coupled to G-proteins (Das et al., 1995) support the possibility that, like cocaine, WIN2 may inhibit noradrenaline-induced accumulation of cAMP. Therefore, a possible interaction between sympathetic neurotransmitters and cannabinoid receptors may occur at the level of cAMP production.

It is also possible that cannabinoids regulate uterine contractility indirectly by modulating production of prostaglandins (PGEs). THC has been shown to elevate PGE levels in uterus venous blood (Jordan and Castracane, 1976). Prostaglandins such as PGE2and PGF2α have been found to increase the force of spontaneous contractions (Krall et al., 1984). The action may also lead to a downregulation of cAMP synthesis because PGE2 and PGF2α have been found to inhibit cAMP accumulation in rat myometrium (Krall et al., 1984; Goureau et al., 1990).

Interaction between bladder and uterus
The potency of WIN2 on uterine motility was reduced in rats with bladder inflammation. One possible mechanism for this viscero-visceral interaction is that bladder inflammation influences the sensitivity of uterine CB1 receptors by way of the hypogastric nerves. In support of such neurogenic control of uterine motility from the bladder is that HYPX both significantly increases the amplitude of spontaneous uterine contractions (Dmitrieva et al., 2001) and, as shown here, nearly abolishes the ability of WIN2 to increase contraction amplitude. One possible scenario is that hypogastric afferents from the bladder that have been activated by inflammation (Moss et al., 1997) convey that information to the T13—L3 segments of the spinal cord (Vera and Nadelhaft, 1992), thereby inhibiting the output of presynaptic neurons that synapse on postganglionic neurons in the IMG whose fibers terminate in the uterus (Papka et al., 1996) and, as suggested above, enhance uterine contractility. HYPX would eliminate this route.

The fact that bladder inflammation decreased the potency of the exogenous cannabinoid ligand WIN2 in the uterus suggests that actions of endogenous cannabinoids, especially anandamide, which is abundant in the uterus (Das et al., 1995), might also be influenced by bladder inflammation. Such a situation would compromise healthy uterine functions. A similar situation might exist for other visceral organs because cannabinoid receptors are expressed in many of them (Joy et al., 1999). Furthermore, this modulation might contribute to the phenomenon of "viscero-visceral-referred hyperalgesia" in which pathophysiology in one visceral domain is found to increase pain associated with pathophysiology in another visceral domain (Giamberardino et al., 1997, 2001, 2002; Berkley et al., 2001), as well as to clinical observations demonstrating the co-occurrence of interstitial cystitis, dysmenorrhea, irritable bowel syndrome, and fibromyaglia (Alagiri et al., 1997).

Source, Graphs and Figures: Contrasting Effects of WIN 55212